Insight Into Parkinson\u27s Disease Using Yeast as a Model to Evaluate the Role of Autophagy Genes in alpha-Synuclein Toxicity by Choi, Ray
Eukaryon
Volume 6 Evolving Connections Article 42
3-1-2010
Insight Into Parkinson's Disease Using Yeast as a
Model to Evaluate the Role of Autophagy Genes in
alpha-Synuclein Toxicity
Ray Choi
Lake Forest College
Follow this and additional works at: https://publications.lakeforest.edu/eukaryon
Disclaimer:
Eukaryon is published by students at Lake Forest College, who are solely responsible for its content.
The views expressed in Eukaryon do not necessarily reflect those of the College. Articles published
within Eukaryon should not be cited in bibliographies. Material contained herein should be treated
as personal communication and should be cited as such only with the consent of the author.
This Senior Thesis is brought to you for free and open access by the Student Publications at Lake Forest College Publications. It has been accepted for
inclusion in Eukaryon by an authorized editor of Lake Forest College Publications. For more information, please contact levinson@lakeforest.edu.
Eukaryon, Vol. 6, March 2010, Lake Forest College                                                                                                                                  Senior Thesis 
Insight Into Parkinson’s Disease Using Yeast as a Model to Evaluate the 
Role of Autophagy Genes in α-Synuclein Toxicity 
 
Ray Choi* 
Department of Biology 
Lake Forest College 
Lake Forest, Illinois 60045 
 
Abstract 
 
The misfolding and aggregation of the protein α-
synuclein is the likely cause of Parkinson’s disease 
(PD), a common incurable human neurodegenerative 
illness. A popular hypothesis is that increasing the 
degradation of α-synuclein may protect cells from its 
aggregation and toxicity.  While the cellular organelle, 
lysosome, is pharmacologically implicated in degrading 
α-synuclein, no genetic evidence currently exists.  We 
hypothesized that α-synuclein uses autophagy, an 
ancient route by which damaged proteins enter the 
lysosome. This hypothesis was tested in a budding 
yeast model wherein autophagy was compromised with 
individual autophagy gene knockouts required for the 
nucleation and expansion steps of autophagy. Three α-
synuclein properties were assessed for potential 
increases: aggregation, accumulation, and toxicity. 
Surprisingly, with six genes examined thus far, we only 
observed subtle autophagic regulation of α-synuclein, 
unlike our prediction. To more completely understand 
autophagy-mediated α-synuclein degradation, the 
remaining proteins that comprise the nucleation, 
expansion, and fusion steps need similar examination. 
 
Introduction  
 
As we enter the 21st century, the world must confront a wide 
range of devastating and lethal epidemics such as cancer 
and HIV. However, due to the population’s increasing 
longevity, society is confronting a new class of illness: 
neurodegenerative diseases. These ailments, characterized 
by the selective death of neurons in the Central Nervous 
System (CNS), are some of the most complex biological 
disorders. These illnesses are marked by neurological 
impediments such as motor deficits and memory loss. Some 
well-studied disorders include the prion disease, Alzheimer’s 
disease (AD), Parkinson’s disease (PD), Huntington disease 
(HD), and Multiple Sclerosis (MS). These diseases can be 
further classified into two groups. The first are infectious – 
the disease causing agent is transmitted between people. 
Prion diseases are part of this category. The second are 
non-infectious and non-transmissible (AD, PD, HD, and MS), 
and arise due to genetic mutations (HD, PD, AD), 
sporadically (AD and PD), or as an auto-immune disorder 
(MS; Prusiner, 1982; Muchowski, 2002; Hauser et al. 2006; 
Rojo et al., 2008). All these diseases, however, are 
hallmarked by selective neuronal death and are believed to 
arise due to a protein that misfolds and accumulates in the 
neurons as inclusion bodies (IB). While the protective or 
toxic effects of this agent are currently under debate, 
research in this field has provided us with a better 
understanding of neurodegenerative diseases such as PD 
(Ross et al., 2005). 
________________________________________________ 
*This author wrote the paper as a senior thesis under the direction of Dr. Shubhik 
DebBurman. 
  
 
 
Parkinson’s disease 
Parkinson’s disease (PD) is the second most common 
progressive neurodegenerative disease after Alzheimer’s 
disease in the population over the age of 65 (de Silva et al. 
2002). Currently, 4 million cases of PD are reported around 
the world, with 1.5 million people afflicted in the US. Sadly, 
the number of people with PD is expected to double within 
the next 30 years – ever-increasing the need for a treatment 
(Dorsey et al., 2007). Pathologically, PD is distinguished 
from other neurodegenerative diseases by the loss of select 
dopaminergic neurons in the substantia nigra pars compacta 
(SNpc; Barbosa et al., 1997). This degeneration, which 
results in the impairments of the motor cortex pathway, 
causes the clinical PD symptoms of bradykinesia, rigidity, 
and resting tremors (Schapira, 1999). In 1912, Friederich 
Lewy identified the characteristic trait of PD patients – the 
Lewy body (LB; Forster & Lewy, 1912).   
 Upon post-mortem analysis of PD patient brains, 
the dying and dead dopaminergic neurons of the SNpc are 
found to contain multiple and abnormal Lewy Bodies 
(Muchowski, 2002; Eriksen et al., 2005; Robinson, 2008). 
While many proteins are found in LBs, the major component 
of LBs are misfolded, aggregated, and ubiquinated α-
synuclein (Dixon et al., 2005; Zabrocki et al., 2005). As such, 
α-synuclein is hypothesized to be the cause of PD (Outeiro & 
Lindquist, 2003; Cooper et al., 2006). Although familial 
inheritance of PD is known (15% of total PD cases), most 
causes of PD are sporadic (85% of total PD cases; Thomas 
& Beal, 2007; Figure 1).  
Interestingly, most of our understanding about PD 
comes from the rarer genetic cases, as an imbalance in PD 
research exists (more is known about the genetic than 
sporadic causes of PD). At present, researchers believe that 
sporadic PD is linked to oxidative stress, mitochondrial and 
proteasomal dysfunction, environmental toxins, and the 
impairment of the Ubiquitin-Proteasome System – the major 
route for α-synuclein degradation (Muchowski et al., 2002; 
Dawson & Dawson, 2003; Moore et al., 2005; Cooper et al., 
2006; Thomas & Beal, 2007; Fitzgerald & Plun-Favreau, 
2008). In familial PD, substantial genetic evidence implicates 
mutations in the genes of the PARK locus to PD 
pathogenesis. These mutations have been linked to 
autosomal-dominant or autosomal-recessive inheritance 
(Gasser, 2009). Mutations in the UCHL1, LRRK2, and α-
synuclein genes are linked to autosomal-dominant PD, while 
mutations in the Parkin, PINK1, and DJ-1 genes are found in 
autsomal-recessive PD (Leroy et al., 1998; Zimprich et al., 
2004; Polymeropoulos et al., 1997; Kitada et al., 1998; 
Valente et al., 2004; Bonifati et al., 2003). Of these genes, α-
synuclein is the most studied and linked protein to causing 
PD (Polymeropoulos et al., 1997; Spillantini et al., 1997; 
Chung et al., 2001). Upon further analysis of the LBs, α-
synuclein is commonly found to be misfolded and 
accumulated in both idiopathic and genetic cases of PD 
(Giasson & Lee, 2003) . Currently, three familial α-synuclein 
mutations are linked to autosomal-dominant PD. The first is 
A53T, where the amino acid (protein building block) alanine 
is replaced by theronine (Polymeropoulos et al., 1997). The 
second is A30P, where an alanine is replaced with a proline 
(Krüger et al., 1998). The last familial mutant is the E46K 
mutation, where glutamic acid is replaced with lysine  
 
 
Figure 1: Molecular Basis of Parkinson’s disease. (A) The three familial mutations of α-synuclein and mutations of the proteasomal degradation 
pathway are linked to genetic Parkinson’s disease. Genetic mutations represent 5 % of all Parkinson’s cases. (B) Idiopathic changes in α-synuclein, a 
protein believed to be responsible for Parkinson’s, represent 95 % of all cases. Possible mutagens of α-synuclein could be oxidative stress, 
environmental toxins such as pesticides or other harmful chemicals, and or a dysfunctional protein degradation pathway. In both familial and sporadic 
Parkinson’s α-synuclein aggregates form, this leads to the formation of Lewy Bodies, a hallmark in Parkinson’s. It is then believed that these inclusions 
lead to cell death and ultimately to the onset of Parkinson’s and its symptoms.  
(Zarranz et al., 2004). These mutations permit α-synuclein to 
misfold at a faster rate compared to normal α-synuclein 
(Polymeropoulos et al. 1997; George, 2002). Thus, 
conformational changes in α-synuclein could not only lead to 
loss-of-normal-function, but to the increased susceptibility of 
the accumulation and aggregation of α-synuclein (Spillantini 
et al., 1997; Lashuel et al., 2002; Dev et al., 2003). 
Nevertheless, the role α-synuclein has in PD pathogenesis is 
still unknown (Figure 1; Polymeropoulos et al. 1997).  
 
The Folding & Function of the Protein α-Synuclein 
α-Synuclein, a 140-amino acid protein, is an interesting 
protein as it has a natural tendency to misfold and is 
naturally found unfolded in the cell (Weinreb et al., 1996; 
Uversky, 2003). It is expressed throughout the brain, but is 
predominantly found in the dopaminergic, cortical, and 
noradrenergic neurons. Furthermore, it localizes in the pre-
synaptic terminals of neurons (Spillantini et al., 1997; Chiba-
Falek et al., 2007). Within the neurons, α-synuclein is 
cytoplasmically located, but has an especially high binding 
affinity for phospholipids (Kahle et al., 2000). While the 
current function of α-synuclein is unknown, it is implicated in 
dopamine transmission, synaptic vesicle dynamics, and in 
learning and adaptation (Outeiro & Lindquist, 2003). 
 While substantial evidence is found in the PD field, 
much more insight is needed to understand PD 
pathogenesis. Major questions that are currently being 
researched in the field are seeking what role free radicals 
have in oxidative stress and mitochondrial dysfunction and 
how they are linked to PD? Are wild-type (WT) and mutant α-
synuclein toxic to organisms? Is α-synuclein toxic in its 
soluble or insoluble form in vivo? Do Lewy bodies play a 
protective role in neurons or are they harmful? Lastly, what 
cellular mechanism is responsible for α-synuclein 
degradation?  
 
 
 My thesis will focus on this latter topic and 
examine α-synuclein digestion via autophagy. However, 
before I discuss protein degradation, I will review protein 
synthesis. 
 
Normal Protein Synthesis  
α-Synuclein, like all proteins, is initially transcribed in the 
nucleus from DNA into an mRNA molecule. After which, the 
mRNA is exported into the cytoplasm where it is translated 
by ribosomes into an amino acid chain – protein in its 
primary structure. With the help from protein chaperones, 
proteins fold into its secondary (α-helix and β-sheets) and 
tertiary structures. If multiple tertiary proteins interact, the 
resulting protein is in a quaternary state (Englander et al., 
2007). Currently, two mechanistic theories of protein folding 
exist. The first is pre-determined by the amino acid 
sequence of the protein, which depends on cooperative 
structural characteristics. The second model, known as the 
independent unrelated pathway, states that proteins folds 
through intermediate structures, until the final conformation 
is reached (Englander et al., 2007; Krishna et al., 2007). 
After proteins are in its final structure, they are transported 
within the cell, to neighboring cells, or to the extracellular 
matrix – where they will perform their cellular function(s). 
Once their function is fulfilled or if they are no longer needed, 
cells will eventually degrade these proteins. 
 
Protein Degradation Pathways 
Proteins are degraded for multiple reasons; some proteins 
are short-lived and are quickly degraded to prevent further 
function, while other proteins that have mutated or 
improperly folded (initially or due to other factors such as: 
denaturation, environment, or age) are also degraded 
(Englander et al., 2007). If these unnecessary and damaged 
proteins are left in the cell, they may prove toxic and 
subsequently fatal to the cell due to their aberrant functions. 
Therefore, proteins are degraded to maintain and protect 
normal cellular homeostasis (Bader et al., 2007). The 
recycled amino acids are then used in future protein 
synthesis.  
 Cells have evolved two pathways for protein 
degradation: the proteasome and lysosome (Figure 2). 
Proteins found cytoplasmically are degraded by the 
proteasome via the ubiquitin-proteasome pathway (UPP), 
while proteins found in the plasma membrane or 
extracellularly are degraded via the lysosome (some cross-
talk occurs). The α-synuclein protein is unique since it is 
found in the cytoplasm and attached to the plasma 
membrane (Kahle et al., 2000). Due to its dual localization, 
α-synuclein may be potentially degraded by the proteasome 
or by the lysosome. In fact, research shows that the co-
chaperone CHIP (carboxy-terminus of Hsp70 interacting 
protein) may act as a molecular determinant of where α-
synuclein will be degraded; the protein’s TPR domain sends 
α-synuclein to the proteasome, while the protein’s U-box 
domain sends α-synuclein to the lysosome (Shin et al., 2005; 
Engelender, 2008). 
 
The Proteasome & α-Synuclein 
The proteasome is a multi-unit organelle located in the 
cytoplasm and nucleus of the cell that degrades proteins 
(Figure 2; Coux et al., 1996; Bader et al., 2007). Before 
proteins can be degraded by the proteasome, they must be 
tagged by ubiquitin – a signal for degradation – multiple 
times via the ubiquitin-proteasome pathway (Bader et al., 
2007). This process, known as ubiquitination, adds ubiquitin 
with the following enzymes. E1 activates ubiquitin; E2 
conjugates ubiquitin; and E3 ligases, or attaches ubiquitin 
and the protein (Hedge and Upadhya, 2007; van Tijn et al., 
2008). The proteasome, which recognizes this chain of 
ubiquitin, internalizes the protein, but prevents ubiquitin from 
entering and recycles it back into the cell (van Tijn et al., 
2008). Once inside the proteasome, the protein is degraded 
by a large enzyme complex (26s) into reusable amino acids 
(Bader et al., 2007; van Tijn et al., 2008).  
 In several major neurodegenerative disorders, 
defects in the ubiquitin-proteasome pathway, due to genetic 
or environmental factors, may be responsible for IB 
formation and disease pathogenesis. Aberrant mutations in 
ataxin-1 are linked to spinocerebellar ataxia type 1 (SCA1). 
When proteasome is inhibited in mice in the presence of 
mutant ataxin-1, not only did neurodegeneration occur, but 
the mutant proteins formed IBs (Cummings et al., 1999). In 
AD, ubiquitin not only associates with non-degraded tau 
tangles, but is found mutated in AD patients (Morishima-
Kawashima et al., 1993; van Leeuwen et al., 1998). 
Furthermore, the extended polyQ repeats of the huntingtin 
protein prevents proteasomal function (mechanism 
unknown), allowing for the aggregation of huntingtin 
(Impairment of the ubiquitin–proteasome system by protein 
aggregation).  
 Similarly, mutations in genes required for the 
ubiquitin-proteasome pathway are linked to PD 
pathogenesis. In healthy neuronal cells, the Parkin protein, 
an E3 enzyme, labels proteins, such as modified α-
synuclein, for degradation (Kitada et al., 1998; Shimura et 
al., 2001; Schulz, 2008). Additionally, mutations in the 
ubiquitin C-terminal hydrolase-L1 (UCH-L1) protein, a de-
ubiquitinating protein, are also linked to PD pathogenesis 
(Leroy et al., 1998; Liu et al., 2002). Thus, direct genetic 
evidence implicates and supports the hypothesis that 
proteasome dysfunction is a cause of PD. Furthermore, α-
synuclein found in LBs reveal non-degraded and multi-
ubiquinated α-synuclein – reinforcing the proteasome in PD 
(Ghee et al., 2000; Tanaka et al., 2001; Snyder et al., 2003). 
These findings were further strengthened when researchers 
discovered that Parkin deficient Drosophila had PD 
pathology similar to humans (Greene et al., 2003). Lastly, 
chemical inhibition of the proteasome by epoxomicins or by 
MB132 results in reduced cell viability and in the formation of 
PD-like LBs in murine models (Petrucelli et al., 2002; 
McNaught et al., 2004; McNaught & Olanow, 2006). Thus, 
supported by genetic and chemical studies, proteasomal 
dysfunction appears a likely cause of PD pathogenesis. 
 
The Lysosome & α-Synuclein 
Unlike the substantial genetic evidence that implicates the 
proteasome and PD, the role of the lysosome in α-synuclein 
degradation is not supported by the literature. Lysosomes 
are enclosed organelles that contain acid hydrolase 
enzymes and proteases, which degrade proteins and other 
large molecules, such as aged organelles, bacteria, and 
nutrients (de Duve et al., 1955). These materials are 
transported to the lysosome in vesicular bodies via three 
independent pathways. Due to its importance in protein 
degradation, researchers hypothesize that the lysosome has 
a role in degrading α-synuclein. 
 In fact, genetic and pharmacological evidence 
implicates lysosomal dysfunction in other neurodegenerative 
disorders. Mice that lack and have mutations in Cathepsin D 
and Cytacin C, genes required for normal lysosome function, 
are shown to have increased neuronal death, 
neurodegenerative symptoms, and increased risks for the 
earlier onset of AD (Koike et al., 2000; Nixon, 2004; Shacka 
et al., 2007). Furthermore, mice deficient in the beclin-1, an 
autophagy gene, display motor defects and form Lewy 
Bodies (Mizushima et al., 2008). Interestingly, when 
lysosomal activity is stimulated by the chemical Z-Phe-Ala-
diazomethylketone (PADK), the cell increased the clearance 
of toxic proteins linked to AD (Butler et al., 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Cellular Degradation Pathways: Eukaryotic cells have evolved two independent pathways for the degradation of unnecessary cellular 
waste, which helps maintain cellular homeostasis. The first is the Ubiquiting-Proteasome Pathway (UPP). In this trafficking system, only proteins found 
in the cytoplasm and nucleus are degraded. The cells, however, must be poly-ubiquinated before the proteasome will recognize the protein to be 
recycled. Another organelle used to digest waste is the lysosome. Protein embedded in the plasma membrane or extracellularly is degraded by this 
pathway. There are three paths to the membrane. The first is phagocytosis, used for digestion of foreign particles. The second is endocytosis, used for 
the uptake of small solutes and proteins. The third is autophagy. In autophagy the cell eats its old and damaged organelles and protein. The end-
product of both systems releases amino acids and lipids used for future synthesis. α-synuclein, which is found both in the cytoplasm and attached to 
the plasma membrane, is believed to be degraded by both the proteasome and lysosome. 
 
In PD pathology, Lee et al (2004) found that the lysosome 
inhibitors rotenone, Baf, or Cathespin I reduced lysosomal 
degradation and caused the accumulation and  aggregation 
of α-synuclein. Furthermore, Cathepsin D, a protease found 
in the lysosome, is also linked to the degradation of α-
synuclein (Qiao et al., 2008). When Cathepsin D levels are 
reduced, the levels of α-synuclein dramatically increase 
(Sevlever et al., 2008). The possible role of lysosomal 
degradation of α-synuclein came in 2004 where chemical 
inhibition of the lysosome by ammonium chloride increased 
the levels of α-synuclein, which led to eventual cell death 
(Cuervo et al.). Nevertheless, the role of the lysosome in PD 
pathogenesis is still not well understood.  
 
Pathways to the Lysosome 
Proteins and other large molecules destined for lysosomal 
digestion must first bypass the plasma membrane and then 
be transported to the lysosome. This transportation of 
particles is achieved by three independent pathways (De 
Duve & Wattiaux, 1966; Luzio et al., 2007).  
 The first trafficking mechanism is phagocytosis. In 
this process, the cell engulfs foreign pathogens and 
apoptotic cells (De Duve & Wattiaux, 1966; Luzio et al., 
2007). Once these targets have been identified, a signaling  
 
cascade is initiated. This pathway allows for the plasma 
membrane to reorganize and encircle the pathogens in 
vesicles known as phagosomes (Luzio et al., 2007). 
However, no evidence supports α-synuclein degradation 
through the pagocytic-lysosomal pathway as this path 
degrades bacterial agents. 
 The second lysosomal pathway is endocytosis. In 
this route, cells engulf material by invagination of the plasma 
membrane. The formed vesicle then migrates to the 
lysosome. However, during this path, the vesicular body 
matures from an early endosome to a late endosome; the 
latter containing more multivesicular bodies (Luzio et al., 
2007). Current evidence implicates the onset of 
neurodegeneration due to mutations in the endosomal 
sorting complex required for transport (ESCRT). Patients 
with mutations in the vesicular protein sorting2B (VPS) 
develop amyotrophic lateral sclerosis (ALS) and 
frontotemporal dementia (Raiborg & Stenmark, 2009). 
Interestingly, in 2007 Hamamichi et al. found VPS 41 
neuroprotective from α-synuclein-induced degeneration in 
the dopaminergic neurons of Caenorhabditis elegans (C. 
elegans). As such, dysfunctions in ESCRT may be 
responsible for α-synuclein aggregation (Willingham et al., 
2003; Alex Ayala’s thesis).  
 
 
The last trafficking system responsible for 
transport to the lysosome is called autophagy.  
 
The Role & Mechanism of Autophagy in the Cell 
Autophagy was discovered in the 1950s by Christian de 
Duve, the same man who discovered the lysosome (De 
Duve & Wattiaux, 1966). However, autophagy remained an 
obscure process until recently, where it is now at the 
forefront of scientific research (Klionsky, 2007; Levine & 
Koremer, 2008). Literally translated from Greek, Autophagy 
means self-eating. In autophagy, the cell sequesters 
cytoplasmic cargo (old, damaged, and or aggregated 
proteins, old and damaged organelles, and invading 
microorganisms) in a double-membrane lipid vesicle known 
as an autophagosome. This vesicle is then transported to 
the lysosome where the material will be degraded. Three 
classifications of autophagy exist: microautophagy, 
chaperone-mediated autophagy (CMA), and 
macroautophagy (Figure 3; hereafter referred to as 
autophagy; Klionsky, 2007; Levine & Koremer, 2008). Most 
of our understanding and knowledge about autophagy has 
come from macroautophagy, as it has been studied the most 
compared to the other forms of autophagy. My thesis will 
focus on this type of autophagy (Mariño & López-Otín, 2004; 
Bandhyopadhyay & Cuervo, 2007; Suzuki & Ohsumi, 2007; 
Klionsky, 2007; Levine & Koremer, 2008).  
 Generally, autophagy is viewed as a bulk-
degradation apparatus that recycles old and damaged 
proteins and organelles. Furthermore, the universal belief on 
autophagy is that its levels are upregulated in cells facing 
conditions of stress and or starvation (De Duve & Wattiaux, 
1966; Mizushima et al., 2004; Yorimitsu & Klionsky, 2005). 
During these challenging states, the cells consume 
themselves to acquire the necessary nutrients to survive and 
maintain basic functions. During these harsh conditions, 
autophagy non-selectively degrades proteins and organelles 
to acquire these nutrients (Nair & Klionsky, 2005). However, 
autophagy does not only fight stressful states, but is 
maintained at basal in the cell during nutrient rich and stress 
free times (Mizushima et al., 2001; Mariño & López-Otín, 
2004; Nixon et al., 2005). Under these conditions, autophagy 
selectively degrades unnecessary organelles to control 
biogenesis (Nair & Klionsky, 2005).  
Interestingly, if autophagy is over active, this 
process may actually kill the cells (Shintani & Klionsky, 
2004). This process is similar to apoptosis or cell suicide. As 
such, these two mechanisms are categorized as follows: 
apoptosis is called programmed cell death (PCD) I, while 
autophagy is called PCD II (Cardenas-Aguayo Mdel et al., 
2003; Shintani & Klionsky, 2004). Autophagy is viewed as a 
safety net in the cell, preventing unnecessary or improper 
cell death (Shintani & Klionsky, 2004). Therefore, autophagy 
maintains cellular homeostasis and survival during healthy 
and sickly times. 
At the molecular level, autophagy occurs in three 
steps: nucleation, expansion, and fusion. The genes 
responsible for each step in Saccharomyces cerevisiae is 
found in Figure 3.To begin, a signal initiates autophagy by 
activating a pre—autophagosomal structure (PAS; Suzuki & 
Ohsumi, 2007; Levine & Koremer, 2008). This structure is 
located near the vacuole and contains the necessary 
materials (lipids and atg proteins) for forming the 
autophagosome (Suzuki & Ohsumi, 2007; Klionsky & Emr, 
2000). After this signal, the PAS enters the nucleation step 
where it expands into a double-lipid membrane known as the 
phagophore or isolation membrane (Suzuki & Ohsumi, 2007; 
Levine & Koremer, 2008; Figure 3). As the IM grows 
autophagy enters the expansion step. In this stage, the IM 
recognizes and surrounds its cargo (cytoplasm and 
damaged proteins or organelles) and seals close; the final 
vesicle structure is called the autophagosome (Klionsky & 
Emr, 2000). However, before the material is degraded, the 
atg proteins that formed this structure are recycled in the cell 
for further use. Finally, in the last autophagy step, the vesicle 
fuses with the lysosome and the marked material is 
degraded (Suzuki & Ohsumi, 2007). The nutrients are then 
recycled back into the cell for further use.  
But why should we look at autophagy in relation to 
neurodegenerative diseases? Specifically, what role does it 
have in α-synuclein degradation and in PD pathogenesis? 
 
Linking Autophagy to Neurodegeneration 
When mice are deficient in autophagy-related genes 5 or 7 
(Atg 5 or Atg7), these animals begin to show signs of 
characteristic neurodegeneration with neuronal death and IB 
formation; Hara et al., 2006; Komatsu et al., 2006). Similarly, 
autophagy levels increase in mice during the early stages of 
AD, which are evidenced by the increase in 
autophagosomes containing amyloid β protein in AD 
neurons (Yang et al., 2009). Furthermore, when the 
mammalian target of rapamycin (mTOR, a gene required for 
autophagy) is pharmacologically inhibited, clearance of 
polyglutamine proteins in HD increases (Ravikumar, 2004). 
From these results, autophagy appears to serve as a 
neuroprotector and may be a potential pharmacological 
therapy in neurodegenerative diseases.  
 Having established a link between HD and 
autophagy, research turned to discover an autophagic link 
with PD. Currently, no genetic evidence supports 
autophagy’s role in PD. Interestingly, histological evidence 
shows a substantial increase in the levels of 
autophagosomes in the dead and dying neurons of PD 
patients (Anglade et al., 1997 Williams et al., 2006). While 
these observations do not provide a genetic link to PD, the 
pathology is similar to what was seen in AD and HD models 
– suggesting a possible PD – autophagy link. Nevertheless, 
while no genetic evidence exists, some pharmacological 
experiments link autophagy and PD. When rampamycin is 
introduced to cell cultures – inhibiting mTOR – autophagy 
levels increase and help clear α-synuclein (Berger et al., 
2006). On the other hand, when autophagy is inhibited in cell 
cultures with lithium, α-synuclein aggregates in the 
cytoplasm and in autophagosomes (Ferrucci et al. 2008). 
Current evidence shows that autophagy degrades α-
synuclein and that α-synuclein may actually inhibit this 
process, hinting at a possible PD autophagy link (Gomez-
Santos et al., 2007; Bandhyopadhyay & Cuervo, 2007; 
Sarkar et al., 2007; Martinez-Vicente et al., 2008; 
Wyttenbach et al., 2008; Vogiatzi et al., 2008; Kabuta & 
Wada, 2008; Xilouri et al., 2008; Wei et al., 2009).  
 The following question remains: what, if any, role 
does autophagy have in PD? Furthermore, as yeast have at 
least 30 atg genes, is a single atg gene responsible for the 
degradation of α-synuclein (Suzuki & Ohsumi, 2007)? Is a 
complex of genes required to degrade α-synuclein, knowing 
that these proteins interact with each other? Is one 
autophagy step more important than another? These 
questions will be best examined and answered in a budding 
yeast model (Figure 4).  
 
Why Study Autophagy in Budding Yeast? 
While yeast are commonly viewed in relation to 
the production of bread and beer, these organisms have 
become a useful tool in molecular biology. As the 
Saccharomyces cerevisiae, Baker’s yeast, genome has 
been sequenced and is available online, we can easily 
manipulate yeast genetically. Additionally, a knockout library
 
 
 
Figure 3: The steps of macroautophagy (autophagy) and their associated genes. Autophagy, in cells, is at a constant basal level to maintain 
homeostasis and a balance between synthesis and degradation of protein and organelles. However, cells can up-regulate autophagy in stressful and 
or nutrient-poor conditions to help it survive. The three major steps of autophagy are nucleation, expansion, and fusion. In the nucleation step, a pre-
autophagosome structure forms around the target molecule. In the expansion step, the autophagosome is formed and the target completely encircled 
by the lipid bilayer. Also at this stage, autophagic bodies are formed in the autophagaosome. In the last step of autophagy, the autophagaosome binds 
to the lysosome or vacuole and releases its content for degradation. The lysosome will release the end-products of the digestion which are amino 
acids. 
 
 
of all yeast genes is readily available, allowing for the study 
of individual genes. Furthermore, yeast and humans have 
high levels of evolutionary conservations in genes and in 
mechanisms such as cell cycle, intracellular transport, and 
protein synthesis, folding, and degradation (Miller-Flemming 
et al., 2008; Winderickx et al., 2008). Specifically, autophagy 
and its genes are highly conserved between yeast and 
humans (Klisonky & Emr, 2000). Furthermore, autophagy 
genes were fist discovered in and are best understood in 
yeast. Lastly, yeast are cheap, easy to maintain, and 
reproduce quickly, making it possible to perform acquire data 
promptly (Outerio & Lindquist, 2003; Miller-Flemming et al., 
2008; Winderickx et al., 2008). 
The versatility of budding yeast in molecular biology is 
evidenced by its use to study a wide range of protein linked 
neurodegenerative disorders such as prion diseases 
(Sondheimer & Lindquist, 2000), AD (Komano et al., 1998), 
HD (Meriin et al., 2002), ALS (Corson et al., 1998), fronto-
temporal dementia with Parkinsonism linked to chromosome 
17 (FTDP 17; Vandebroek et al., 2006), and PD (Outerio & 
Lindquist, 2003; Willingham et al., 2003).  
 The first α-synuclein yeast model papers were 
published in 2003 (Outerio & Lindquist, Willingham et al.). 
These labs found that wild-type (WT) and A53T α-synuclein 
bind the plasma membrane, form inclusions, alters vesicle 
transport, and induces toxicity in a concentration dependent 
manner (Outerio & Lindquist, 2003, Dixon et al., 2005). 
However, A30P α-synuclein is cytoplasmically diffuse and is 
not toxic to yeast (Outerio & Lindquist, 2003, Dixon et al., 
2005; Soper et al., 2008). Similarly, the Muchowski lab 
preformed a genomic-wide screen and identified 86 
knockout strains that were lethal when overexpressed with 
α-synuclein (Willingham et al. 2003). Nevertheless, their 
findings successfully reproduced the findings established by 
other labs (Willingham et al., 2003 ).These results then 
suggest that α-synuclein localization at the plasma 
membrane may be toxic to cells (Dixon et al., 2005).  
 In our lab, we have also reproduced the findings in 
the field. Budding yeast that expressed WT and A53T α-
synuclein localized at the plasma membrane, while A30P α-
synuclein was cytoplasmically diffuse (Sharma et al., 2004). 
However, we did not observe toxicity in any of our yeast 
expressing these synucleins (Sharm et al., 2004). We have 
also examined the third known α-synuclein mutant: E46K 
(Zarranz et al., 2004) E46K α-synuclein localized to the 
plasma membrane and was more toxic than the other 
familial mutants (Herrera Thesis, 2004; White Thesis, 2004). 
Furthermore, Michael Zorniak, who examined mitochondrial 
dysfunction, found decreased α-synuclein expression, no 
cellular toxicity, and for formation of intracellular aggregates 
in one of his two examined strains (2007). Lastly, we found 
that the formation of α-synuclein aggregates was dependent 
on α-synuclein expression levels (Kukreja, 2008). 
Additionally, when DMSO was applied to budding yeast, α-
synuclein localized in unidentified cytoplasmic structures and 
had an α-synuclein independent toxicity (Kukreja, 2008).  
 While our lab has had similar results to other yeast 
labs, this summer (2008) we discovered an error in the 140th  
 
 
 
 
Figure 4: Saccharomyces cerevisiae autophagy knockout 
models. In WT and knockout yeast, we induced ɑ-synuclein 
expression through our galactose promoter region. The normal cells 
should degrade ɑ-synuclein via the autophagy-lysosome pathway 
and will be a healthy cell. However, in the Atg knockout yeast, we 
hypothesize that the increased ɑ-synuclein expression will not be 
degraded by autophagy. Thus, ɑ-synuclein will aggregate in our yeast 
model and prove toxic. 
 
 
amino acid of our α-synuclein – where a glycine residue was 
mistaken for an alanine residue (Sharma, 2004). Upon 
discovery, we quickly corrected all our α-synuclein 
constructs to the correct α-synuclein – 140 Alanine. Since 
then, we have repeated major findings in our lab and found 
that most α-synuclein properties remained the same 
between the α-synuclein – 140 Alanine and the α-synuclein 
– 140 Glycine constructs. These results were expected as 
the difference between glycine and alanine is a methyl side 
chain – a conservative difference – should have no 
substantial impact on the folding of the protein. Furthermore, 
we did not find any suggestions that the 140th amino acid of 
α-synuclein undergoes modification in the literature. Thus, 
having established a viable model organism with 
evolutionary conservation with humans, our budding yeast 
will provide insight into autophagy’s role in α-synuclein 
degradation and PD pathogenesis in humans (Miller-
Flemming et al., 2008). 
 
Hypothesis & Aims 
 
My hypothesis was that autophagy is a route for α-synuclein 
degradation by the lysosome and I tested this hypothesis 
using a genetic approach in budding yeast. Of the 30 plus 
autophagy genes discovered and characterized in yeast, my 
thesis examined a total of six genes: four from the nucleation 
step and two from the expansion step. 
 Aim 1: To compromise nucleation step genes (Atg 
17 and VPS15) by individual gene knockout strains in 
budding yeast and to examine if α-synuclein changed its 
cytoplasmic localization away from the plasma membrane, 
increased cellular accumulation, and made the cells more 
toxic 
Aim 2: To compromise expansion step genes (Atg 
1, Atg2, Atg8, and Atg 18) by individual gene knockout 
strains in budding yeast and to examine if α-synuclein 
changed its cytoplasmic localization away from the plasma 
membrane, increased cellular accumulation, and made the 
cells more toxic 
Aim 3: To compare the pathological properties of 
α-synuclein – 140 Glycine to α-synuclein – 140 Alanine and 
to test the prediction that little to no change would be  
observed between  them.  
 
Results 
 
The following results provide data for the two autophagy 
steps (nucleation and expansion) analyzed in their regulation 
of α-synuclein toxicity in budding yeast. A total of six 
knockout strains, two nucleation genes (Atg17 and VPS 15) 
and four expansion genes (Atg1, Atg2, Atg8, and Atg18), 
were compared with the isogenic parent BY4741 strain. 
Each strain was analyzed with two control vectors: pYES2 
and GFP, and three α-synuclein-GFP vectors. The pYES2 
construct verifies that introduction of the plasmid does not 
affect yeast; while the GFP construct ensures that the GFP 
protein is not toxic to the yeast. The three α-synuclein 
vectors examined were WT (linked with sporadic PD) and 
A30P and E46K (both familial PD mutants). We used four 
assays to examine α-synuclein’s PD linked properties. 
Toxicity was measured with OD600 growth curves and 
spotting analysis. Expression and accumulation were 
measured with Western blot analysis. α-Synuclein 
localization was visualized with live cell GFP microscopy. 
 
α-Synuclein Presents Well Known Characteristics in Parent 
BY4741 Strain 
As previously published (Sharma et al., 2006), WT α-
synuclein was predominantly at the plasma membrane and 
not toxic in BY4741 (Fig. 5). A30P α-synuclein localized 
diffusely throughout the cell and was not toxic (Sharma et 
al., 2006). Lastly, E46K α-synuclein localized to the plasma 
membrane and was not toxic (White et al, manuscript in 
prep). α-synuclein characteristics in this strain will serve as 
comparative controls for the autophagy compromised strains 
examined below because these knockout strains are derived 
from and are genetically isogenic to BY4741. 
 
α-Synuclein Accumulation Alters in Nucleation Compromised 
Strain vps15Δ  
Our first goal was to determine if α-synuclein expression 
would affect growth in nucleation compromised vps15Δ 
yeast. vps15Δ cells grew at an equal rate, irrespective of 
whether they expressed α-synuclein or not, but they 
exhibited a non- α-synuclein-dependent delayed growth 
when compared to BY4741 (Fig. 6). While the literature 
shows that vps15Δ yeast are viable, no evidence suggests a 
delay in growth compared to WT (Giaever et al., 2002). 
Serial spotting analysis confirmed growth curve observations 
(Fig. 6). Thus, we did not observe the toxicity in vps15Δ 
predicted by our hypothesis. Next, we measured α-synuclein 
accumulation in vps15Δ cells with Western Blot analysis and 
noted a marked decrease of α-synuclein expression in A30P 
cells, but not in WT, E46K, or GFP cells.  Lastly, α-synuclein 
localization in WT and E46K cells was initially more 
heterogeneous (a combination of plasma membrane 
 
 
localization and intracellular aggregates) in vps15Δ 
compared to predominantly plasma membrane localization in 
BY4741. A30P intensity was initially lower but reached 
BY4741 levels by 48 hours. 
 
α-Synuclein Alters its Localization in Nucleation Comprised 
Strain atg17Δ 
To evaluate specificity or universality of regulation by 
nucleation step genes, a second gene knockout strain, 
atg17Δ, was studied. Surprisingly, atg17Δ cells expressing α-
synuclein grew better than cells that did not express 
synuclein (Fig. 7). However, serial spotting plates 
contradicted the growth curve data (Fig. 7), making it difficult 
to fully interpret the impact on toxicity. Western Blot analysis 
showed no change in synuclein expression in atg17Δ cells, 
but showed a marked decrease in GFP alone expression 
(Fig. 7). Lastly, atg17Δ cells decreased GFP fluorescence 
over time. In atg17Δ cells, WT and E46K α-synuclein 
localization shifted from polarized plasma membrane 
localization to full plasma membrane localization with some 
intracellular aggregates.  A30P did not alter its localization.  
Collectively, these results suggest subtle regulation of the 
nucleation genes vps15Δ and atg17Δ in degrading α-
synuclein as some, but not all, α-synuclein properties 
examined were altered. 
 
α-Synuclein Alters its Localization in Expansion Comprised 
Strain atg18Δ 
Next we examined the expansion step in autophagy, by first 
evaluating the atg18 gene. Again, contrary to our hypothesis, 
all atg18Δ cells, with or without synuclein, grew at a 
comparable rate to BY4741 cells (Fig. 8). Western blots 
revealed no change in atg18Δ α-synuclein expressing cells 
compared to BY4741, but we observed decreased GFP 
alone expression in cells (Fig. 8). Plasma membrane 
localization of E46K became more intense over time in 
atg18Δ when compared to BY4741 cells, but remained 
constant for WT or GFP alone. While A30P was initially 
diffuse, it formed more intracellular aggregates over time 
than it does in BY4741. 
 
Several α-Synuclein Properties Affected in Expansion 
Comprised Strain atg2Δ 
Next, to evaluate specificity or universality of regulation by 
expansion genes, we examined a second gene, atg2. 
Growth curves demonstrated that α-synuclein cells had a 
delayed growth compared to the other atg2Δ cells, 
suggesting some toxicity (Fig. 9). However, serial spotting 
plates did not capture this reduced WT growth (Fig. 9). 
Interestingly, Western analysis showed increased 
accumulation of WT synuclein and GFP alone, but not A30P 
or E46K, when compared to expression in BY4741 cells (Fig. 
9). Importantly, all forms of α-synuclein (WT A30P, and 
E46K) localized as intracellular aggregates over time, losing 
their initial membrane localization (WT and E46K) of 
cytoplasmically diffuse status (A30P), showing significant α-
synuclein dependent change (Fig. 9). 
 
α-Synuclein Alters its Localization in Expansion Comprised 
Strain atg8Δ 
Because the expansion step involves at least ten genes, we 
examined another gene knockout, atg8Δ. Irrespective of 
whether they expressed α-synuclein or not, atg8Δ cells grew 
at an equal rate to BY4741 (Fig. 10). Serial spotting analysis 
confirmed this observation (Fig. 10). Western blot analysis 
revealed no changed in accumulation when compared to 
BY4741 cells (Fig. 10). Lastly, live cell microscopy in atg8Δ 
revealed unexpected intracellular aggregate formation of not 
just α-synuclein variants but also of GFP alone, indicating a 
non-synuclein-dependent localization effect. 
 
α-Synuclein Alters its Localization in Expansion Comprised 
Strain atg1Δ 
Lastly, we examined another expansion gene atg1. 
Irrespective of whether they expressed α-synuclein or not, 
atg1Δ cells grew at an equal rate to BY4741 (Fig. 11). Serial 
spotting confirmed this analysis (Fig. 11).  Western blot 
analysis revealed no change in accumulation when 
compared to BY4741 cells (Fig. 11). Lastly, live cell 
microscopy in atg1Δ cells revealed unexpected intracellular 
aggregate formation in GFP and A30P α-synuclein 
expressing cells over time, while WT and E46K α-synuclein 
remained unchanged when compared to BY4741 cells (Fig. 
11). 
Collectively, these results suggest subtle 
regulation of the expansion genes in degrading α-synuclein. 
In atg2Δ yeast, we observed changes in growth and 
localization. In atg18Δ yeast, E46K and A30P localization 
were α-synuclein, but the other properties were untouched. 
Interestingly, atg8Δ  had little impact on α-synuclein specific 
properties, but instead, its effect on protein localization 
appeared more global. Lastly, atg1Δ did not appear to have 
significant effects on α-synuclein specific properties. 
 
Does α-Synuclein’s 140th Amino Acid Matter? 
During the summer of 2008, our lab discovered a mutation in 
our α-synuclein construct where the terminal 140th amino 
acid was a mutant (glycine) instead of the correct amino acid 
(alanine). We, therefore, corrected all of our α-synuclein 
constructs and proceeded with experimentation (as seen 
with the above results). However, before this discovery, my 
autophagy research (and that done by my two colleagues, 
Alina Konnikova and Julian Mclain) had utilized the α-
synuclein constructs that carried the glycine mutant in four 
knockout strains (atg1Δ, atg2Δ, atg17Δ, and atg18Δ). Here, I 
will provide a brief summary of results we obtained and 
compare it to the α-synuclein data derived from the corrected 
amino acid (See Appendix figures: 1 – 5) 
 
1. Serial spotting analysis revealed no difference between α-
synuclein – 140 Glycine and α-synuclein – 140 Alanine, in 
any of the four strains tested (compare B in Appendix figures 
1 – 5). 
 
2. Growth curves reveal no differences between α-synuclein 
– 140 Glycine and α-synuclein – 140 Alanine, as above. 
However, one notable change was that E46K growth was 
rescued in α-synuclein – 140 Alanine (compare A in 
Appendix figures 1 – 5). 
 
3. Live cell microscopy of all vector constructs (α-synuclein – 
140 Glycine and α-synuclein – 140 Alanine) in atg1Δ, atg2Δ, 
atg17Δ, and atg18Δ strains are mostly comparable to 
BY4741, with some subtle exceptions (compare D in 
Appendix figures 1 – 5).  
 
4. Lastly, Western blot analysis revealed reduced 
accumulation of E46K α-synuclein – 140 Glycine in BY4741 
compared to atg1Δ , atg2Δ, atg17Δ, and atg18Δ. However, 
E46K α-synuclein – 140 Alanine expression was comparable 
to atg1Δ, atg2Δ, atg17Δ, and atg18Δ (compare C in 
Appendix figures 1 – 5). 
 
Together, these results reveal that most of the α-synuclein 
properties examined were similar, with some subtle changes 
between α-synuclein – 140 Glycine and α-synuclein – 140 
Alanine. 
 
 
Discussion 
 
While substantial genetic evidence links α-synuclein 
degradation via the proteasome, increasing evidence 
implicates autophagy mediated lysosomal degradation 
(Webb et al., 2003; Gomez-Santos et al., 2007; 
Bandhyopadhyay & Cuervo, 2007). Nevertheless, this 
hypothesis in the field is still tentative as more research is 
required. As such, my thesis investigated autophagy’s role in 
the clearance of α-synuclein in yeast cells. We inquired 
whether autophagy knockouts would be toxic in 
Saccharomyces cerevisiae expressing α-synuclein. We 
hypothesized an increase in α-synuclein related toxicity in 
our autophagy deficient strains, due to increased 
accumulation. Our results, however, lead to three notable 
conclusions as they unexpectedly did not show dramatic 
changes in the α-synuclein properties examined. First, we 
found subtle regulation of α-synuclein in our knockout 
strains. Secondly, different autophagy knockouts had 
different effects on the α-synuclein properties in BY4741. 
Lastly, none of the genes examined has an effect on α-
synuclein toxicity. Nonetheless, while our results do provide 
some insight into autophagy’s role in α-synuclein’s PD 
pathogenesis, more research is needed for conclusive 
results. 
 
Subtle Regulation of α-Synuclein in Autophagy Knockouts 
Contrary to our hypothesis, the six-autophagy genes we 
examined did not have major effects on α-synuclein related 
PD pathogenesis. Instead, the knockouts we studied had 
subtle alterations in the three examined α-synuclein 
properties. Furthermore, not all properties investigated were 
affected in each knockout strain. For example, while growth 
in α-synuclein expressing atg17Δ yeast grew faster than 
BY4741, the other properties of this strain were mostly 
unaffected, but still comparable to BY4741. Similarly, atg2Δ 
mutants revealed a dramatic shift in α-synuclein localization 
(foci formation), but growth and accumulation were 
comparable to BY4741. 
 While our results predominantly show α-synuclein 
alterations in one of four assays (change in localization, but 
not in toxicity or accumulation), these results cannot exclude 
autophagy from having a role in α-synuclein PD 
pathogenesis. Past research with yeast gene knockout 
strains have demonstrated α-synuclein regulation without 
affecting all known PD-linked properties. Previous research 
of oxidative stress in our lab has shown extensive α-
synuclein related toxicity in the sod1Δ and sod2Δ strains, but 
no change in α-synuclein localization (Sharma et al., 2006).  
Research in the Gitler lab (2009) shows similar 
impairments to single assays of their PD yeast model. They 
found that the overexpression of Ypk9 rescued BY4741 
yeast from α-synuclein induced toxicity, but observed no 
alteration in the other α-synuclein properties. Similarly, 
Flower et al. (2005) found increased toxicity in their Sac3Δ, a 
heat shock protein, FY23 yeast strain, but found no change 
in α-synuclein expression. Even though our current results 
mostly show subtle autophagic regulation of α-synuclein 
properties in one assay, we cannot decidedly determine 
autophagy’s potential role in PD pathogenesis as single 
changes have significant consequences in our own and 
other labs’ yeast models. 
 Thus, despite its subtle role, autophagy can still be 
implicated in our yeast model. As previously stated, 
autophagy is required for basic cellular homeostasis and 
maintenance. As seen in figure 3, autophagy is a complex, 
multi-step pathway composed of at least 30 genes (Suzuki & 
Ohsumi, 2007). Since each autophagy step contains at least 
seven genes, one or two of these genes of the overall 
process may play a critical role in PD pathogenesis. For 
example, two autophagy genes in mice had an important 
role in basal autophagy and in the onset of 
neurodegeneration: Atg5 and Atg7 (Komatsu et al., 2006; 
Hara et al., 2006). Mice deficient in either gene, in the 
absence of other mutations, displayed characteristic 
symptoms of neurodegeneration. Furthermore, when beclin 
1 (yeast homologue: apg6p) expression is reduced in mice, 
they show earlier-than-expected AD pathogenesis (Pickford 
et al., 2008). To this extent, our research has only examined 
a fraction of the relevant autophagy genes of the nucleation 
and expansion steps in yeast. Therefore, we have yet to 
determine if a critical gene(s) exists in PD pathogenesis. 
 While a potential autophagy gene may exist, our 
results may be due to redundancies that exist in the 
autophagic pathway – at least 30 genes are responsible for 
this complex pathway (Suzuki & Ohsumi, 2007). Even 
though we examined subtle changes of α-synuclein in our 
nucleation and expansion knockouts, another atg gene of 
the same step may compensate for this loss of function. 
Yang et al. (2006) found that atg22p, in yeast, has 
overlapping functions with avt3p and avt4p – vacuolar efflux 
proteins. Additionally, mammalian atg1 is known to have 
redundant functions (Lee et al., 2007). Therefore, nucleation 
and expansion genes may have possible complementary 
and or redundant roles in yeast, leading to the subtle 
changes observed. As with critical autophagy genes, this 
redundancy has yet to be established in yeast.  
Proteins do not act independently in the cell, but 
function together as a large piece of machinery; autophagy 
proteins are no exception. Most, if not all, autophagy genes 
perform their functions as part of a large complex of proteins. 
Atg1 forms complexes with Atg13 and Atg17; it also forms a 
complex with atg11 (Kamada et al. 2000; Kabeya et al., 
2005). Furthermore, the Atg12, Atg5, Atg7, Atg10, and Atg16 
complex is required for autophagosome formation (Wang & 
Klionsky, 2003). In 2005, Cheong et al. found that their 
atg17Δ yeast had only minor autophagy defects. This finding 
suggests that even if we were to remove a protein required 
for autophagy complexes, we would not hinder this process, 
but rather make in inefficient. Thus, the alteration we 
observed in some α-synuclein properties in our six atgΔ 
strains could be explained by autophagy’s reduced 
functionality.  
 
Not All Autophagy Genes Affect α-Synuclein Similarly 
Despite the subtle changes we observed in our autophagy 
knockout strains, each knockout strain had interesting and 
differing effects on the α-synuclein properties examined. 
Most of the strains studied had only one major change in our 
four evaluations, with some subtle, if any, changes in the 
other assays. In atg17Δ, α-synuclein appears not to be toxic 
as these constructs allow yeast to grow faster. In atg8Δ 
yeast, α-synuclein localization in A30P and E46K changed 
over time when compared to BY4741. However, we did 
notice two strains that did have changes in more than one of 
our assays. The first was atg2Δ; in this strain, α-synuclein 
localization dramatically changed over time and WT α-
synuclein had a growth delayed compared to the four other 
constructs. The second strain was vps15Δ where growth, 
localization, and accumulation in one α-synuclein construct 
were altered.  
 Similar to the idea that one autophagy gene is 
important for α-synuclein degradation, not all autophagy 
genes have an equal role in this catabolic process (Suzuki & 
Ohsumi, 2007). In autophagy, of the 30 known genes thus 
far, 16 of these genes are part of the basic machinery 
needed to form the IM, while the 14 other genes work in 
concert with these basic proteins (Suzuki & Ohsumi, 2007; 
Mari & Reggioir, 2007). Of the six genes we examined, all 
genes, but atg17, are required for the core autophagy 
 
 
machinery (Xie & Klionsky, 2007). Additionally, certain genes 
are known to be more functionally important than others in 
this process. One protein of great importance is atg9 – part 
of the core proteins. The function of atg9 is to sequester the 
lipid membranes needed for the formation of the PAS (Xie & 
Klionsky, 2007). When this gene is loss, autophagy is greatly 
hindered (Lang et al., 2000). Taken together, our knockouts 
may have less importance in the autophagic pathway than 
other genes. Furthermore, they may have a less specific role 
in degrading α-synuclein. However, due to the limited 
research on the six genes I studied, we cannot state their 
important role in autophagy or in the degradation of α-
synuclein. 
 
No Effects on α-Synuclein Related Toxicity in Autophagy 
Knockouts 
While my data may implicate α-synuclein regulation by 
autophagy due to the change in its localization, these results 
are a stark contrast to our prediction on toxicity. As 
previously stated, the most surprising result we obtained was 
in our atg17Δ yeast where the three α-synuclein constructs 
grew at a faster rate than that of our controls. However, we 
did observe some toxicity as vps15Δ yeast grew at a slower 
rate than that of our control. Even WT α-synuclein showed 
some delayed growth in our atg2Δ yeast. Nevertheless, 
these strains did not reveal the toxicity we expected, nor did 
the three other examined strains.  
 As aforementioned, some compensation in the 
nucleation and expansion steps of autophagy may be due to 
possible redundancies in the pathway. However, this 
complementary effect is not limited to autophagy genes 
themselves, but can be expanded to three other degradation 
pathways in yeast: proteasomal degradation, apoptosis, and 
chaperone-mediated autophagy. As previously stated, α-
synuclein can be degraded by both the proteasome and the 
lysosome. Therefore, α-synuclein in our autophagy knockout 
yeast may be increasingly degraded by the proteasome, or 
at least at sufficient levels to prevent noticeable toxicity in 
these yeasts. Webb et al. (2003) have shown that inhibition 
of either the proteasome or autophagy causes an 
upregulation in activity of the other respective pathway, 
suggesting some levels of compensation (Ding et al., 2007; 
Settembre et al., 2007; Raben et al., 2008; Venkatachalam 
et al., 2008; Zhang et al., 2009) 
This similar effect is observed in another pathway 
to maintain the health of an organism. Apoptosis, like 
autophagy, is an example of programmed cell death (PCD). 
Due to their similarity in cellular function, these two pathways 
are tightly related and have some compensatory effects. 
Two proteins that regulate and differentiate between PCD I 
and PCD II are the DAPk and DRP-1 family of proteins 
(Shintani & Klionsky, 2004; Mizushima et al., 2008). Due to 
the tight regulation between the two PCDs, the results of 
these papers suggest that inhibition of autophagy may lead 
to increases in apoptotic activity and vice versa (Maiuri et al., 
2009; Mizushima et al., 2008). In 2006, a paper showed that 
caplain cleavage of Atg5 induced apoptosis (Yousefi et al., 
2006). Furthermore, loss of the bax protein in mice, 
upregulated autophagy, while loss of Atg 5 or Atg 7 
increased apoptosis in neuronal cells (role of bcl-2 family 
proteins in a non-apoptotic programmed cell death 
dependent on autophagy genes; Hara et al., 2006; Komatsu 
et al., 2006). Therefore, yeast that were overcome by α-
synuclein related toxicity increased their apoptotic response 
early in their growth to help maintain the populations survival 
(Chronological aging leads to apoptosis in yeast). 
Nevertheless, apoptosis in yeast, as well as the link between 
the two PCD mechanisms are not fully understood. Thus, 
more research is required before this hypothetical 
connection can be established. 
A last compensatory mechanism for autophagy is 
CMA. Unlike autophagy, CMA undergoes a molecule by 
molecule degradation pathway. Specific proteins are 
sequestered by a chaperone protein that transports this 
complex to the lysosome. Nevertheless, while these two 
pathways are mostly independent, recent genetic evidence 
reveals cross-talk between autophagy and CMA as lowered 
CMA activity increased autophagy levels (Kaushink et al., 
2008). The opposite effect is also observed (Massey et al., 
2006; Kaushik et al., 2008). However, these results show 
only partial compensation due to the redundancies between 
the two autophagys. Taken together, one pathway is not 
enough to compensate for the other. Nevertheless, the 
partial CMA compensation may be enough to have 
prevented the toxicity we expected in our autophagy 
knockout strains (Kaushik et al., 2008). 
A last explanation for this lack of observable 
toxicity may be linked to the physical traits of yeast – their 
stress response. For example, yeast used to brew beer must 
respond to different temperatures, oxidative conditions, and 
pH levels must adapt to these stressful conditions to survive 
(Gibson et al., 2007). Therefore, the yeast stress response is 
particularly adept to helping these organisms survive a 
variety of harsh and unstable environments. This same 
survival skill may be activated in my autophagy deficient 
yeast; in addition to the upregulation of the three other 
degradation pathways. With these results, we cannot 
exclude an autophagic regulation of α-synuclein related PD 
toxicity. 
 
Only Subtle Differences Between α-Synuclein – 140 Glycine 
and α-Synuclein – 140 Alanine Constructs 
While the data from this thesis may or may not implicate 
autophagy in α-synuclein degradation, our results, 
nevertheless, supported our third aim: there would be little or 
no change between the two α-synuclein constructs. One 
reason we did not expect any change is that the difference 
between α-synuclein – 140 Glycine and α-synuclein – 140 
Alanine is due to the conservative difference between amino 
acids – a methyl group. To begin, the methyl group is a 
microscopic addition when compared to the entire protein. 
Second, this group does not change the polarity of the 
protein as hydrogen and methane do not carry an overall 
charge. These two factors should then not affect the tertiary 
structure of the protein significantly. Lastly, α-synuclein that 
is found in Lewy Bodies is known to undergo post-
translational modification at the following sites: 12th, 21st, 
23rd, 87th, 115th, 119th, 122nd, 129th, 133rd, and 135th (Fujiwara 
et al., 2002; Anderson et al., 2006), but no known 
modification is known to occur on α-synuclein at the 140th. 
Therefore, since the terminal amino acid does not appear to 
have great functional importance, there should be subtle 
changes, if any, between the α-synuclein constructs. 
The most notable change between the two α-
synuclein constructs came in BY4741 Western Blots. The 
E46K expression in the corrected α-synuclein increased 
compared to mutant α-synuclein (Fig x. appendix x). 
Secondly, corrected E46K was no longer toxic compared to 
the mutant α-synuclein. In our knockouts strains, the most 
prominent change between the two α-synuclein constructs 
was with the shift in localization. Even with these changes in 
corrected α-synuclein, the α-synuclein properties did not 
dramatically differ from the mutant α-synuclein. We can 
therefore conclude that the data from three years of research 
in our lab are still valid for reference and that the 140th amino 
acid has slight alterations on α-synuclein. 
 
Criticisms and Limitations 
While we believe that autophagy is dysfunctional in our 
knockout strains, we never measured autophagy. Therefore, 
 
 
we cannot determine if autophagy has ceased. Instead of 
directly measuring autophagy, we measure its effects 
indirectly. Furthermore, once we ensure autophagy 
deficiency, FM4-64 staining will ensure that α-synuclein is 
sent to and degraded by the lysosome. Finally, evaluation of 
the other atg genes and inducing autophagy in our atg 
knockouts will help elucidate the possible genetic links 
between α-synuclein degradation and autophagy.  
 
Future Studies 
The first studies to be preformed will be the complete 
analysis of all remaining nucleation, expansion, and fusion 
genes. We will also need to verify α-synuclein localization to 
the lysosome with FM4-64 staining. The next steps will be to 
analyze induced autophagy with different nutrient starvation 
conditions, chemical upregulation of autophagy, or other 
stress promoting environments. (As of yet, we have only 
studied basal autophagy). With these experiments, we will 
have a better understanding of autophagy’s role in 
controlling α-synuclein related toxicity. Additionally, all these 
experiments will need to be repeated in fission yeast as a 
complete knockout library is now available. As a last study, 
we will need to examine if other degradation pathways are 
compensating for the loss of autophagy. 
 
Conclusion 
 
The goal of this research was to establish a connection 
between autophagy and α-synuclein related PD 
pathogenesis. While our results surprisingly did not reveal 
the toxicity we expected, autophagy did appear to subtly 
regulate the degradation of α-synuclein. The most significant 
change we observed was the mislocalization of α-synuclein 
from the parent BY4741 strain. Nonetheless, we cannot 
decidedly state if autophagy play or does not play a role in 
degrading α-synuclein as more research must be conducted.  
However, if we are able to establish an autophagic 
– PD link, the potential for PD treatments greatly arise. In 
other neurodegenerative disease, scientists hypothesize that 
upregulation of autophagy may remove toxic protein 
aggregates in HD (Ravikumar et al., 2004; Sarkar et al., 
2007). It may also be possible to use this increased activity 
to prevent the onset of disease; a similar treatment option 
may be available to PD patients (Pan et al., 2008). Taken 
together, establishing an autophagic genetic link with PD 
could potentially help improve the quality of life in PD 
patients. 
 
Methods 
 
Methods described in detail in Sharma et al 2006. 
 
α-Synuclein Constructs  
A30P and E46K α-synuclein were produced using site-directed 
mutagenesis (Invitrogen) from WT α-synuclein – sequencing was 
confirmed by the University of Chicago. A53T α-synuclein cDNAs and 
human WT α-synuclein were a gift from Christopher Ross (Johns 
Hopkins University). WT and mutant α-synuclein cDNAs were 
subcloned into the pYES2.1/V5-His-TOPO yeast expression vector 
(Invitrogen).  All α-synuclein cDNAs were subcloned into the 
mammalian expression vector pcDNA3.1/C-terminal GFP (Invitrogen) 
where they were fused with GFP at the C-terminus. These α-
synuclein constructs were PCR-amplified and subcloned into 
pYES2.1/V5-His-TOPO yeast expression vector (Invitrogen). 
Chemically competent E. coli cells were transformed with the α-
synuclein, α-synuclein-GFP, and GFP-−α-synuclein pYES2.1/V5-His-
TOPO vectors.  
All α-synuclein – 140 Glycine constructs were 
reconstructed to α-synuclein – 140 Alanine using site-directed 
mutagenesis. The following primers were used:  
 
 
Gal-1 forward primer  
5’-AATATACCTCTATACTTTAACGTC-3’ 
 
V5C-term Reverse primer 
 5’-ACCGAGGAGAGGGTTAGGGAT-3 
 
All α-synuclein – 140 Alanine constructs were confirmed by 
sequencing (University of Chicago). 
 
α-synuclein Expression Vectors 
The pYES2.1/V5-His-TOPO DNA vector (Invitrogen) was used for α-
synuclein expression in budding yeast. Four constructs were 
previously created for each experiment: green fluorescent protein 
(GFP), wild-type α-synuclein, A30P α-synuclein, and E46K α-
synuclein. The pYES2.1/V5-His-TOPO DNA vector and the GFP 
tagged vector were used as controls (See Table 1 for List of 
Constructs).  
 
Yeast Strains:  The BY4741 (MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0) 
and atgΔ knockout strains (atg1Δ, atg2Δ, atg8Δ, atg17Δ, atg18Δ, and 
vps15Δ) were purchased from Open Biosytsems.   
 
Transformation of Yeast Strains:  The GFP and α-synuclein WT, 
A30P, and E46K plasmids were transformed into BY4741, atg1Δ in 
4741, atg2Δ in 4741, atg8Δ in 4741, atg17Δ in 4741, atg18Δ in 4741, 
and vps15Δ in 4741. All plasmids had C-terminus GFP tags in the 
pYES2.1/V5-His-TOPO vector. Transformations were confirmed by 
whole-cell yeast polymerase chain reaction (PCR). 
 
α-Synuclein Expression:  α-synuclein and GFP expression was 
regulated by a galactose inducible promoter (GAL1) within the 
pYES2.1/V5-His-TOPO. Yeast were grown in SC-Uracil glucose 
overnight for analysis. The glucose media suppressed α-synuclein 
expression. The yeast were centrifuged (2500 rpm at 4 °C for 5 min) 
and then washed. This process was repeated twice to insure glucose 
removal. The yeast were then inoculated in SC-Uracil galactose and 
incubated at30 °C and 200 rpm shaking to induce α-synuclein 
expression.  
 
Growth Curve Analysis:  Cells were grown overnight in 5 mL of SC-
Uracil glucose at 30 °C and 200 rpm shaking. The cells were 
centrifuged (2500 107 cells were removed, pelleted, and re-
suspended in 1 mL of water.  Each culture had 100 µL transferred to 
a 96-well microtiter plate and were serially diluted, 5-fold, across the 
plate. The cultures were then plated onto three SC-Uracil galactose 
and three SC-Uracil glucose plates.  Each plate was then incubated 
at 30 °C and photographed 2 days post-growth. 
 
GFP – Live Cell Fluorescent Microscopy:  1ml of cells were taken 
from a parallel running Growth Curve and pelleted at 14,000 rpm 24 
and 48 hours post-α-synuclein expression. The galactose media was 
poured off and the cells were re-suspended in the remaining media. 
10 µL of each culture was pipetted onto a glass slide with a cover 
slip. All images were taken using a Nikon TE2000-U fluorescent 
microscope at 1000X magnification and Metamorph 6.0 software. 
Cells were first viewed with differential interference contrast (DIC), 
and then the fluorescence images of the same cells were taken. A 
minimum of 750 cells for each culture were examined. 
rpm for 5 min at 4 °C) and washed. This process was repeated twice. 
Cells were re-suspended in 10 mL of nanopure H20 and counted 
using a hemocytometer. Flasks with 25ml SC-Uracil galactose were 
inoculated to a cell density of 2.0 x 106 cells/mL and incubated at 30 
°C and 200 rpm shaking for 48 hours.  At 0, 3, 6, 12, 18, 24, 36, and 
48 hours post-galactose innoculation, cell density was measured by 
pipetting 1 mL from each culture, in duplicate, into a cuvet.  The 
cuvets were analyzed using a Hitachi U-2000 spectrophotometer to 
determine culture density.  Average absorbance versus time was 
plotted on a graph for growth curves. 
 
Growth Analysis through Cell Spotting:  Cells were grown overnight in 
5 mL of SC-Uracil glucose at 30 °C and 200 rpm shaking. The cells 
were centrifuged (2500 rpm for 5 min at 4 °C) and washed. This 
process was repeated twice. Cells were re-suspended in 10 mL of 
nanopure H20 and counted using a hemocytometer. A density of 2.0 x  
 
Western Blotting:  Cells were grown in SC-Uracil glucose overnight. 
They were harvested and centrifuged at 2500 rpm at 4 °C for 5 min 
then washed with water (repeated twice). The cells were then 
 
 
transferred to SC-Uracil galactose. Cells were taken 24 and 48 hours 
post-α-synuclein expression and counted to a density of 2.5 x 107. 
The cells were centrifuged at 14,000 rpm in order to make cell 
lysates. Electrophoresis -solubilizing buffer (ESB) was added to each 
colony, heat shocked at 100°C, and lysed using small glass beads. 
The ESB contains numerous protease inhibitors and Sodium Dodecyl 
Sulfate (SDS) detergent. The lysates were stored at -20 °C. Tris-
glycine gels (Invitrogen) were used to run the cell lysates. 10 µL of 
See Blue mass ladder (Invitrogen) was used to determine protein 
mass. 20 µL of each cell lysate was transferred into the gel and ran at 
130 V with 1X running buffer (29.0 g Tris-Base, 144.0 g Glycine, 10.0 
g SDS, 1 L H2O, and pH 8.7). The protein in the gel was transferred 
to PVDF membranes using the Semi-Dry Transfer apparatus 
(Biorad). Anti-V5 monoclonal (Invitrogen) antibody was used to 
analyze α-synuclein expression, while anti-Phosphoglycerate Kinase 
(PGK, Invitrogen) was used for loading control. The immunodetection 
protocol from Invitrogen Western Breeze kit was used to detect the 
alkaline phsophatase activity. The gel was dried and photographed. 
 
 
 
Table 1. List of Transformed Budding Yeast Strains 
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